BiomX Inc. (PHGE)
Oxford Ledge is still expanding full research coverage of PHGE. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Clinical-stage company developing phage-based therapies to treat bacterial infections using natural and engineered viruses.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Other material event; Financial statements and exhibits 2026-07-10
- 8-K 4.01; Financial statements and exhibits 2026-07-02
- S-1 IPO / securities registration statement 2026-06-29
- 8-K Shareholder vote results; Financial statements and exhibits 2026-06-26
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-06-18
Source: SEC EDGAR.
Annual results
5 years of annual figures for PHGE, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | — | -$36.2M | $22.19 |
| 2024 | — | -$17.7M | $58.31 |
| 2023 | — | -$26.2M | $5.10 |
| 2022 | — | -$28.3M | $0.95 |
| 2021 | — | -$36.2M | $1.39 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for PHGE. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open PHGE in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.